Sheldon Okada
About Sheldon Okada
Sheldon Okada is the VP of Business & Commercial Strategy with 20 years of experience in the biopharmaceutical industry, focusing on commercial and financial roles, and has contributed to the launch of several FDA-approved drugs.
Sheldon Okada - VP, Business & Commercial Strategy
Sheldon Okada currently serves as the Vice President of Business & Commercial Strategy. With a 20-year career in the biopharmaceutical industry, he has expertise in both commercial and financial roles. His focus is on supporting the development and patient access to transformative therapies.
Sheldon Okada - Education and Expertise
Sheldon Okada holds a Master of Science in Chemistry from the California Institute of Technology. He also has a Bachelor of Arts in Molecular and Cell Biology from the University of California, Berkeley. This educational background has equipped him with a comprehensive understanding of the scientific foundations critical to the biopharmaceutical industry.
Sheldon Okada - Background
Before becoming VP at his current organization, Sheldon Okada spent 14 years at Gilead Sciences. During this time, he held various roles within the Commercial Strategy and Financial Planning groups. He played a crucial role in launching four FDA-approved drugs and supporting development programs in infectious diseases, liver disease, and inflammation.
Sheldon Okada - Achievements
As Senior Director of Commercial Strategy at Forty Seven Inc., Sheldon Okada established the commercial function and supported development strategies. He was also involved in early launch preparations for Forty Seven's lead oncology program. His contributions at Gilead Sciences include the launch of four FDA-approved drugs, emphasizing his impact on driving successful commercial strategies.